Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025

Page 3 of 14

12. Elicio Therapeutics Inc (NASDAQ:ELTX)

Number of Hedge Fund Holders In Q3 2024: 1

Elicio Therapeutics Inc (NASDAQ:ELTX) is a biotech company that makes lymph node-targeted immunotherapies.

The stock has risen sharply so far in 2025 as it secured FDA agreement on some elements of its registrational Phase 3 trial design for ELI-002.

The company achieved full enrollment in its Phase 2 AMPLIFY-7P trial in Q1 2024. Interim DFS analysis is expected in the first half of this year.

Early data has shown a 28.9-month median DFS in Phase 1 patients receiving the 4.9mg dose, with T-cell responses correlating to reduced recurrence risk.

Plus, it raised $10 million via a registered direct offering priced at $7.925 per share.

The consensus price target of $10 implies 7.41% upside.

ELTX stock is up 72.55% year-to-date.

Page 3 of 14